Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Biogen Idec (NQ: BIIB ) 224.94 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, May 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Biogen Idec < Previous 1 2 3 4 5 6 7 8 9 ... 43 44 Next > 10 Health Care Stocks With Whale Alerts In Today's Session March 20, 2024 Via Benzinga 10 Health Care Stocks With Whale Alerts In Today's Session March 19, 2024 Via Benzinga 10 Big-Name Stocks Near 52-Week Lows: Are They A Buy? March 16, 2024 Over the past twelve months a number of big named companies have been near or below their 52 week low price. Each week we’ll take a look at some of the biggest names currently close to their 52 week... Via Talk Markets Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings March 14, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire A Closer Look at 21 Analyst Recommendations For Biogen March 05, 2024 Via Benzinga Biogen Unusual Options Activity February 29, 2024 Via Benzinga Fed Rate Cut Expectations Rise After February Jobs Report: Friday's Stock Movers March 08, 2024 February labor report shows mixed signals: increase in non-farm payrolls but higher unemployment rate and downward revisions. Wage growth lower than expected, fueling bets on Fed rate cuts. Stocks... Via Benzinga Topics Economy Exposures Interest Rates Are These 5 Undervalued Stocks Ready to Break Out? March 08, 2024 Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices. Via MarketBeat Eli Lilly's Donanemab For Alzheimer's Hits FDA Speed Breaker, Biogen Stock Gains On Delayed Decision March 08, 2024 The FDA's upcoming advisory committee meeting on Eli Lilly's Phase 3 donanemab trial for early symptomatic Alzheimer's. Understand safety and efficacy considerations, with a delay in expected FDA... Via Benzinga Exposures Product Safety Peering Into Biogen's Recent Short Interest February 19, 2024 Via Benzinga FDA Delays Decision On Eli Lilly's Alzheimer Drug March 08, 2024 The FDA will hold an advisory panel for Lilly's Alzheimer drug donanemab. Via Investor's Business Daily Exposures Product Safety Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers March 06, 2024 Biogen's latest SMA research! Interim data from the RESPOND study reveals promising outcomes with SPINRAZA treatment. Learn about reduced NfL levels and the impact on infants and children with spinal... Via Benzinga New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy March 06, 2024 From Biogen Inc. Via GlobeNewswire Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting March 04, 2024 From Biogen Inc. Via GlobeNewswire Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits March 04, 2024 Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising. Via InvestorPlace 1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223? March 02, 2024 Getting its Alzheimer's medicine approved in the European Union could be big. Via The Motley Fool Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit) February 29, 2024 Nvidia Corp. is one of the leading top stocks with 60% gain in 2024, but other lesser-known names have outperformed. Via Benzinga BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Biogen Stockholders and Encourages Investors to Contact the Firm February 24, 2024 From Bragar Eagel & Squire Via GlobeNewswire Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors February 23, 2024 From Glancy Prongay & Murray LLP Via Business Wire Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP February 23, 2024 From Biogen Inc. Via GlobeNewswire 3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024 February 22, 2024 With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year. Via InvestorPlace INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors February 22, 2024 From Law Offices of Howard G. Smith Via Business Wire The Law Offices of Frank R. Cruz Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors February 21, 2024 From The Law Offices of Frank R. Cruz Via Business Wire From Zero to Hero: 7 Stock Losers That Could Turn Things Around in 2024 February 19, 2024 Although these companies suffered earlier, they could become stock turnarounds as investors recognize their potential. Via InvestorPlace 7 Contrarian Biotech Stocks to Consider Amid Sector Weakness February 15, 2024 Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts. Via InvestorPlace Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says February 14, 2024 Biogen's Leqembi launch challenges impact stock growth; Spinraza faces competition. Analyst lowers price target to $316, citing uncertainties. Via Benzinga Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday February 14, 2024 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga Biogen (BIIB) Q4 2023 Earnings Call Transcript February 13, 2024 BIIB earnings call for the period ending December 31, 2023. Via The Motley Fool Topics Earnings Exposures Financial Markets Tumble, VIX Up 8% On Hot Inflation Data, Dollar, Yields Jump As Traders Unwind Rate Cut Bets: What's Driving Markets Tuesday? February 13, 2024 Wall Street witnessed one of the worst sessions since the beginning of the year, with widespread declines across the board as stocks were hit by the impact of a higher-than-expected inflation report. Via Benzinga Topics Economy Stocks Exposures Interest Rates US Equities Why Is Biogen Stock Trading Lower On Tuesday? February 13, 2024 Biogen's Q4 2023 performance, with $2.39 billion in sales, adjusted EPS of $2.95, and updates on key drugs. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 43 44 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.